CETP Inhibitors Back In The Fold: Amgen Dives In With Dezima Buy
This article was originally published in The Pink Sheet Daily
TA-8995 is potentially best-in-class and could fill a void in Amgen's portfolio for an oral agent, Exec VP R&D Sean Harper says in an interview. Development will focus on LDL-C lowering, not HDL-C increases.
You may also be interested in...
Start-Up Quarterly Statistics, Q3 2015
Start-ups raised $2.57 billion in Q3. Biopharma companies penned 23 alliances; 11 acquisitions were signed, none in the diagnostics industry.
PCSK9 Mechanism Lends Confidence Ahead Of Outcomes Data
With a well-defined mechanism of action and positive post hoc outcomes data, PCSK9 inhibitors possess a profile that raises the bar for other non-statin classes – CETP in particular.
IMPROVE-IT’s Mixed Blessing: How Low Does LDL Really Need To Go?
Sponsors of injectable PCSK9 biologics address questions about the implications of the IMPROVE-IT study, in which the soon-to-be-generic oral Zetia helped bring down LDL cholesterol to a very low level.